CARM vs. CTSO, XGN, AWH, LFVN, ADVM, PRLD, GBIO, RENB, OMER, and PBYI
Should you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Cytosorbents (CTSO), Exagen (XGN), Aspira Women's Health (AWH), LifeVantage (LFVN), Adverum Biotechnologies (ADVM), Prelude Therapeutics (PRLD), Generation Bio (GBIO), Renovaro (RENB), Omeros (OMER), and Puma Biotechnology (PBYI). These companies are all part of the "medical" sector.
Carisma Therapeutics (NASDAQ:CARM) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.
Carisma Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Cytosorbents has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
Cytosorbents has a net margin of -75.07% compared to Carisma Therapeutics' net margin of -538.81%. Cytosorbents' return on equity of -129.89% beat Carisma Therapeutics' return on equity.
Cytosorbents received 424 more outperform votes than Carisma Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Carisma Therapeutics an outperform vote while only 79.13% of users gave Cytosorbents an outperform vote.
44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 17.0% of Carisma Therapeutics shares are held by company insiders. Comparatively, 6.6% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Carisma Therapeutics presently has a consensus price target of $9.00, indicating a potential upside of 576.69%. Cytosorbents has a consensus price target of $2.00, indicating a potential upside of 122.20%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Carisma Therapeutics is more favorable than Cytosorbents.
Cytosorbents has higher revenue and earnings than Carisma Therapeutics. Cytosorbents is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Carisma Therapeutics had 1 more articles in the media than Cytosorbents. MarketBeat recorded 4 mentions for Carisma Therapeutics and 3 mentions for Cytosorbents. Carisma Therapeutics' average media sentiment score of 0.96 equaled Cytosorbents'average media sentiment score.
Summary
Carisma Therapeutics beats Cytosorbents on 10 of the 17 factors compared between the two stocks.
Get Carisma Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Carisma Therapeutics Competitors List
Related Companies and Tools
